Form 4: Boundless Bio Director Kristina Burow Granted 16,000 Stock Options

Kristina Burow, a Director and 10% Owner of Boundless Bio, Inc., was granted 16,000 stock options with an exercise price of $1.03, vesting over 12 months starting June 23, 2025.

Summary

• Kristina Burow, a Director and 10% Owner of Boundless Bio, Inc. (BOLD), was granted 16,000 stock options.
• The options have an exercise price of $1.03 per share.
• The grant date for these options is June 23, 2025.
• The options will vest in substantially equal monthly installments over 12 months following June 23, 2025.
• Alternatively, any remaining unvested portion will vest on the date of the next annual meeting of stockholders if it occurs prior to June 23, 2026.
• Vesting is contingent upon Ms. Burow's continued service on the issuer's board of directors.
• The options expire on June 22, 2035.
• Following this transaction, Ms. Burow beneficially owns 16,000 derivative securities directly.

Sentiment

Score: 7

Explanation: The document reports a standard equity compensation grant to a director, which is a neutral to slightly positive event as it aligns interests. There are no negative financial implications or red flags within this specific filing.

Positives

• The grant of stock options aligns the interests of a director and significant shareholder (10% owner) with the long-term performance of the company.
• The vesting schedule incentivizes continued service on the board of directors.

Risks

• The value of the stock options is dependent on the future stock price of Boundless Bio, Inc., which is subject to market fluctuations and company performance.
• Vesting is subject to continued service, meaning the options could be forfeited if the director's service ceases.

Future Outlook

The stock options are designed to vest over a 12-month period following June 23, 2025, or earlier upon the next annual meeting, contingent on the director's continued service, indicating an expectation of ongoing board involvement.

Industry Context

This is a standard compensation practice for directors in publicly traded companies, including those in the biotechnology sector, to align their interests with shareholders.

Comparison to Industry Standards

• The grant of stock options to directors is a common practice across industries, including biotechnology, as a form of equity compensation.
• The vesting schedule over 12 months is a relatively short-term vesting period for director options, though it aligns with incentivizing continued service for the upcoming year.
• The exercise price of $1.03 is likely the fair market value of the stock on the grant date, which is standard for incentive stock options.

Related Party Transactions

• The grant of 16,000 stock options to Kristina Burow, a Director and 10% Owner, constitutes a related party transaction as it involves compensation to an insider.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholders by incentivizing long-term stock performance. It also represents a potential future dilution if options are exercised, though this is a standard part of equity compensation plans.

Next Steps

• Continued service of Kristina Burow on the Boundless Bio, Inc. board of directors.
• Monthly vesting of the 16,000 stock options over 12 months starting June 23, 2025.
• Potential acceleration of vesting if the next annual meeting occurs before June 23, 2026.

Key Dates

Keywords

Boundless Bio, BOLD, Kristina Burow, Stock Option, SEC Form 4, Insider Transaction, Director Compensation, Equity Grant, Vesting Schedule, Biotechnology, Pharmaceuticals